Inventor · disambiguated record
David Gailani
Also filed as: GAILANI DAVID
9 granted patents·2 pending applications·146 citations·filing 2008–2018
90Inventor score
Top patents by PatentIndex Score
11 records- 0195US9636399B2Anti-factor XI monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2015·Granted May 2, 2017·15 cites·22 claims
- 0295US8236316B2Anti-factor XI monoclonal antibodies and methods of use thereofGRUBER ANDRAS·Filed 2008·Granted Aug 7, 2012·33 cites·24 claims
- 0394US9125895B2Anti-factor XI monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2014·Granted Sep 8, 2015·19 cites·15 claims
- 0493US8388959B2Anti-fXI antibodies and methods of useGRUBER ANDRAS·Filed 2009·Granted Mar 5, 2013·29 cites·22 claims
- 0591US9637550B2Anti-fXI antibodies and methods of useUNIV OREGON HEALTH & SCIENCE·Filed 2014·Granted May 2, 2017·14 cites·21 claims
- 0691US8940883B2Anti-fXI antibodies and methods of useUNIV OREGON HEALTH & SCIENCE·Filed 2013·Granted Jan 27, 2015·15 cites·12 claims
- 0791US8399648B2Polynucleotides encoding anti-factor XI monoclonal antibodies and methods of use thereofGRUBER ANDRAS·Filed 2012·Granted Mar 19, 2013·14 cites·14 claims
- 0883US9574013B2Antibodies against factor XII and uses thereofUNIV VANDERBILT·Filed 2013·Granted Feb 21, 2017·7 cites·20 claims
- 0969US10577428B2Anti-factor XI monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2018·Granted Mar 3, 2020·0 cites·19 claims
- 1062US2017204195A1Anti-factor xi monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2017·Application pending·0 cites
- 1162US2013171144A1Anti-factor xi monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Gailani files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →